Skip to content

MDMA Induces Caspase‐3 Activation in the Limbic System but not in Striatum

Ilaria Tamburini, Fabio Blandini, Marco Gesi, Giada Frenzilli, Marco Nigro, Mario Giusiani, Antonio Paparelli, Francesco Fornai

Annals of the New York Academy of Sciences August 1, 2006 DOI: 10.1196/annals.1369.037 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Experimental study Peer reviewed
Population Rodents
Intervention MDMA
Topics MDMA
Keywords Striatum Amygdala Piriform cortex Hippocampus Limbic system Basal ganglia Basal forebrain
Citations 24
Key findings MDMA induces caspase-3 activity in the amygdala and hippocampus but not in the striatum or frontal cortex.

Abstract

Abstract: Several studies, carried out in chronic (+/−) 3,4‐methylenedioxymethamphetamine (MDMA) abusers, have shown memory loss and cognitive impairment, as well as persistent electroencephalographic changes. This suggests that, at least in humans, forebrain areas, including the limbic system, might be altered by MDMA. Consistently, recent experimental evidences suggest that, in rodents, MDMA, besides effects on the basal ganglia, produces alterations in the hippocampus. Therefore, the aim of the present article was to investigate whether treatment with MDMA produces activation of the caspase‐3 enzyme, which is part of an enzymatic pathway involved in cell death, within limbic areas (i.e., hippocampus, amygdala, and piriform cortex) and striatum. A marked induction of caspase‐3 activity was demonstrated in the amygdala and hippocampus, although MDMA did not affect caspase‐3 activity neither in the striatum nor in the frontal cortex. These data indicate that limbic structures possess a high sensitivity to MDMA with respect to the activation of at least one step in the apoptotic pathway. Potential implications and pitfalls of such an experimental observation are reported.

Comparable studies

Other preclinical and animal studies on MDMA, most cited first.

Study Year Design Participants
Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Rats (implied by typical neurochemical study context) 1987 Experimental study
3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Rat brain 1987 Animal experiment
Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs Human and mouse dopamine, norepinephrine, and serotonin transporters expressed in cells 2006 In vitro laboratory study
Small Changes in Ambient Temperature Cause Large Changes in 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonin Neurotoxicity and Core Body Temperature in the Rat Rats 1998 Experimental study
Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery Squirrel monkeys treated with MDMA 1999 Observational cohort

Citations in the library

Cited by 15

and 10 more in the library

Cites 3

Related reading

Explore topics

MDMA